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Health care utilization among patients with chronic kidney disease. The growing incidence and prevalence of end-stage
Background. Higher hospitalization rates among end-stage renal disease (ESRD), and the rising resource expendi-
renal disease (ESRD) patients impose a substantial burden on tures related to the care of ESRD patients are a causethe U.S. health care system. Early identification of patients with
for concern [1]. In the United States, the prevalence ofchronic kidney disease (CKD) and determination of factors as-
ESRD doubled in the last decade [2] and is expected tosociated with increased morbidity may lead to appropriate in-
terventions to attenuate the complications of CKD and possibly rise further as the U.S. population ages and medical
reduce future resource utilization. advances result in prolonged survival of individuals with
Methods. This retrospective cohort study of CKD patients chronic illnesses. The total annual cost of care of thein an outpatient nephrology clinic was performed to identify
ESRD population in the U.S. was estimated to be $17.9risk factors for hospitalization. The study population consisted
billion in 1999 [3], and is expected to exceed $20 billionof adults with elevated serum creatinine (females 1.5 mg/dL,
males 2.0 mg/dL). Hospitalizations, hospital days and outpa- in the year 2000 [2, 4]. Hospitalizations account for a large
tient nephrology visits were examined. fraction of the cost of care in this population, followed
Results. Among the 259 patients, 123 (47%) were hospital-
by dialysis and non-dialysis physician and supplier costsized during a median follow-up of 11.4 months. The number of
[3]. The most recent data from the United States Renalhospitalizations and hospital days per patient-year at risk were
0.96 and 6.6, respectively. Cardiovascular disease/hypertension Data System (USRDS) reveal that between 1996 and
accounted for the majority of hospitalizations. In a multivariate 1998, the average ESRD patient had 1.9 hospitalizations
regression analysis, older age (RR 1.01, 95% CI 1.00, 1.03) and and spent 14 days in hospital each year [5].
presence of cardiac disease (RR 1.91, 95% CI 1.19, 3.07) were
Analyses of large national databases and single-centerassociated with higher risk of hospitalization while higher se-
experiences have improved our understanding of the fac-rum albumin (RR 0.58, 95% CI 0.35, 0.95) and higher hemato-
crit (RR 0.92, 95% CI 0.87, 0.97) were associated with lower tors associated with a higher risk of hospitalization among
risk of hospitalization. Higher serum albumin (RR 0.34, 95% ESRD patients [6–8]. The majority of hospitalizations
CI 0.21, 0.55), higher hematocrit (RR 0.87, 95% CI 0.81, 0.93) among ESRD patients appear to be for the managementand use of ACE-inhibitors (RR 0.63, 95% CI 0.47, 0.84) were
of complications and comorbid conditions that may beginassociated with lower risk of subsequent hospital days. Erythro-
to arise early during the course of chronic kidney dis-poietin (RR 1.47, 95% CI 1.11, 1.82) use was associated with
higher risk of outpatient nephrology visits. ease (CKD). These conditions progressively worsen with
Conclusion. Certain potentially modifiable factors appear advancing kidney failure and result in a substantial pro-
to be associated with increased resource utilization. It is hy- portion of patients having severe complications by thepothesized that attention to these factors may lead to improved
time they begin renal replacement therapy. Thus, pa-outcomes in this patient population, which could result in re-
duced utilization. tients with CKD are an ideal target for interventions
aimed at reduction of morbidity and mortality among
ESRD patients. Resource utilization in this group is
likely to have a substantial economic impact, since esti-
mates from the Third National Health and Nutritional
Examination Survey (NHANES III) suggest that 6.2 mil-Key words: renal disease, hospitalization, outpatient visit, end-stage
renal disease, risk for hospitalization, generalized estimating equation. lion U.S. residents have serum creatinine levels 1.5
mg/dL [9], a conservative estimate of the prevalence ofReceived for publication June 12, 2001
CKD. A better understanding of the rates, causes andand in revised form February 25, 2002
Accepted for publication February 27, 2002 risk factors for hospitalization among CKD patients
would allow estimates of the economic burden of CKD, 2002 by the International Society of Nephrology
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identification of patients at risk for increased resource mary. The causes of hospitalization were categorized
as: cardiac/hypertension, congestive heart failure/volumeutilization, and selection of interventions that could re-
duce morbidity, mortality and costs in these populations. overload, hemodialysis access related, peritoneal dialysis
access related, infection, metabolic (includes electrolyte
abnormalities and diabetic ketoacidosis), peripheral vas-
METHODS
cular disease, acute kidney failure or progression of
Patient population chronic kidney failure, psychiatric/central nervous sys-
tem/cerebrovascular, gastrointestinal, kidney/genitouri-This is a retrospective cohort study of adult (age 18
years or older) patients with CKD followed in the outpa- nary, malignancy, and others.
tient Nephrology clinic at New England Medical Center
Definitions and equations(NEMC) in Boston, Massachusetts, between October
1994 and September 1998. CKD was defined for purposes The presence and severity of comorbid conditions was
determined using the index of disease severity (IDS)of this study as serum creatinine 1.5 mg/dL for women
and 2.0 mg/dL for men on at least two consecutive score developed by Greenfield and Nelson [10] and later
modified by Athienites et al for use in ESRD patientsoccasions. The study patients were selected by reviewing
the serum creatinine levels and diagnoses of all patients [11]. The modified IDS score stages the severity of twenty
major medical conditions. Five common comorbid condi-identified as having a nephrology clinic visit during the
study period in the computerized utilization database of tions were separately determined: cardiac diseases, pe-
ripheral vascular disease, cerebrovascular disease, hyper-NEMC. Patient data were collected from the first date
of service during the study period that criteria for CKD tension and diabetes. Hypercholestrolemia was defined
as serum cholesterol 200 mg/dL and/or use of lipid-were met until the start of dialysis, transplant, transfer
to another facility, loss to follow-up, end of study (Sep- lowering agents. Abnormal calcium-phosphorus metab-
olism was defined as a parathyroid hormone (PTH) leveltember 31, 1998), or death, whichever occurred earlier.
100 pg/dL and/or serum phosphorus level 4.5 mg/dL
Data collection and categorization and/or use of calcitriol and/or phosphate binders. Acido-
sis was defined as a serum bicarbonate level20 mmol/L.Clinical and laboratory data were extracted from the
conventional and electronic medical records of NEMC Glomerular filtration rate (GFR) was estimated using
a prediction equation derived from the results of theusing a computerized data collection form designed for
the study. Collected data included demographic charac- Modification of Diet in Renal Disease (MDRD) Study,
which is based on age, gender, race, and serum creatinineteristics, insurance status, clinical parameters, use of medi-
cations, and laboratory values at baseline. Longitudinal (abstract; Levey et al, J Am Soc Nephrol 11:155A, 2000).
data were collected on clinical parameters, use of medi-
Statistical analysiscations, and laboratory values at each nephrology visit.
When laboratory values were not available for a given Summary descriptive statistics of baseline characteris-
tics were performed for the entire population and forvisit, laboratory values nearest to the date of the visit
within 45 days before or after the visit were entered. All subsets of patients with and without hospitalizations.
Results of continuous variables are presented as meanhospitalizations at NEMC from within 90 days prior to
the first study visit until September 31, 1998 were re- standard deviation (SD), and discrete variables as pro-
portions. Baseline characteristics of patients with andcorded, with the intent to capture all hospitalizations at
NEMC within the four fiscal years of the study among without hospitalizations after the first study visit were
compared using Student t test or Pearson chi-square test,patients followed for CKD. Race was categorized as
Caucasian, African American, Asian or other. Insurance as appropriate.
All hospitalizations within 90 days prior to the firstwas categorized as private, health maintenance organiza-
tion (HMO), Medicare, Medicaid and none. Cause of study visit until the end of study were used to calculate
the hospitalizations and hospital days per patient-yearCKD was classified as diabetes, hypertension, glomeru-
lonephritis/interstitial nephritis/polycystic kidney dis- at risk. Time at risk was calculated from the first study
visit or hospitalization (if within 90 days prior to the firstease (GN/IN/PKD) and others. Medications recorded in
the clinic chart were assumed to be used by the patients, study visit), whichever came first, to the start of dialysis,
transplant, transfer to another facility, loss to follow-up,and actual medication adherence could not be deter-
mined given the retrospective nature of the study. The end of study, or death. The total number of hospital days
was subtracted from time at risk for analyses of hospital-primary cause of hospitalization was considered to be
the diagnosis listed as primary on the discharge summary. ization and outpatient nephrology visits. The number of
hospitalizations and number of hospital days per patient-Among the multiple secondary causes listed, the most
fitting diagnosis accounting for the hospitalization was year at risk were obtained by dividing the total number
of hospitalizations and hospital days observed by thedetermined after careful review of the discharge sum-
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total calculated patient-years at risk of the entire cohort. of such outcomes and the interpretation is more familiar,
and (2) the GEE method theoretically captures more pre-The relationship between number of hospitalizations and
hospital days was determined by obtaining the Pearson cisely factors which change over time that may have a
potential impact on hospital utilization, such as hemato-correlation coefficient.
The end points assessed in regression analyses were crit, serum albumin and level of kidney function. Statisti-
cal analyses were performed using SAS System for Win-time to first hospitalization, number of hospitalizations,
hospital days, and number of outpatient nephrology vis- dows, version 8.00 (SAS Institute Inc., Cary, NC, USA).
its. Three different types of analyses were explored to de-
scribe the relationship between patient characteristics
RESULTS
and risk for utilization. A traditional Cox proportional
A total of 272 patients satisfied study criteria for CKDhazards regression was used to examine the association
during the study period. Thirteen patients were excludedbetween baseline demographic, clinical and laboratory
because no information was available after the initialvariables and time to first hospitalization after the initial
study visit, thus the final study cohort was composed ofstudy visit. A Poisson regression multiple event model
259 patients. Median follow-up was 11.4 months (rangewas developed to examine the association between base-
0 to 47.7 months). Eight percent of the patients pro-line demographic, clinical and laboratory variables and
gressed to ESRD during the time frame of the study,each of the following resource utilization outcomes: (1)
10% were transferred to other facilities, 2% died, 30%number of hospitalizations, (2) number of hospital days,
were lost to follow-up, and 50% were followed in clinicand (3) number of outpatient nephrology visits. The over-
until the study end date.dispersion parameter was estimated by dividing the Pear-
son statistic by the degrees of freedom (df). The loga-
Patient characteristics
rithm of the follow-up period was used as the offset
The mean age of the patients was 62  16 years, 54%parameter in the fitted Poisson model to adjust for vary-
were male and 75% were Caucasian. The cause of CKDing time spans among patients. Lastly, generalized esti-
was diabetes in 26%, hypertension in 22%, GN/IN/PKDmating equation (GEE) methodology with an exchange-
in 27% and a variety of other causes in 26%. The majorityable correlation matrix was used to analyze the different
of patients had substantial comorbidity. Hypertensionutilization outcomes. Robust standard error estimates of
was present in 87%, diabetes in 35%, cardiovascularthe coefficient were used. These estimates have the prop-
disease in 40%, and peripheral vascular disease in 14%.erty of being consistent estimators of the standard errors
Among 259 patients, 123 (47%) were hospitalized dur-even if the working correlation matrix is specified incor-
ing the study period. The baseline demographic and clini-rectly. The GEE technique incorporates multiple obser-
cal characteristics of patients with and without hospital-vations of the patient characteristics being evaluated.
izations are provided in Table 1. Hospitalized patientsThus, in addition to evaluating the relative risk of multi-
were older (P  0.001), had a lower prevalence of GN/ple events, changes over time in independent variables
IN/PKD as cause of CKD (P  0.001), and had a higherare captured. The probability of having a hospitalization,
prevalence of cardiac disease (P  0.001), diabetes (Phospital day or an outpatient nephrology visit at any given
0.006), cerebrovascular disease (P  0.001), and periph-day during the follow-up period was estimated. For these
eral vascular disease (P  0.002) compared to patientslongitudinal analyses, missing variables were handled
without hospitalizations. Other factors were not signifi-as follows: categorical variables, such as medication use,
cantly different between the two groups.were carried over from the previous visit, whereas for
The laboratory characteristics and medication usecontinuous variables, such as hematocrit or albumin, the
among patients with and without hospitalizations areaverage of the values before and after the visit with the
provided in Table 2. Patients who were hospitalized hadmissing covariate was calculated. The results of the Pois-
a lower serum albumin (P 0.001) and hematocrit (Pson and GEE regression express the relative risk (RR)
0.006) and less frequent angiotensin converting enzymeof having the first or future events of any of the repeated
(ACE) inhibitor use (P  0.045) compared to patientsoutcomes; for example, with hospital days, the result ex-
without hospitalizations.presses the relative risk of a future hospital day, that is, a
more prolonged hospitalization. All multivariate models
Hospitalizationswere constructed using stepwise selection of indepen-
There were 0.96 hospitalizations and 6.6 hospital daysdent variables with probability values of 0.10, except
per patient-year at risk. The causes of hospitalizationage, gender, race and diabetes, which were forced into
are shown in Figure 1. Cardiac disease and hypertensionthe model. The results of the traditional Cox propor-
(cardiac/HTN), which includes all cardiovascular causestional hazards analysis and the GEE analysis are pre-
except congestive heart failure, was the most commonsented for the following reasons: (1) the results of the
Cox model are more easily compared to other studies primary diagnosis of the hospitalizations, accounting for
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Table 2. Laboratory characteristics and medication useTable 1. Demographic and clinical characteristics of patients
with chronic kidney disease among patients with chronic kidney disease
Hospitalized Non-hospitalizedHospitalized Non-hospitalized
(N  123) (N  136) P a (N  123) (N  136) P a
Creatinine mg/dL 2.71.0 2.81.2 0.50Age 6514 5816 0.001
Male 53% 56% 0.62 GFR mL/min/1.73 m2 26.810.4 26.39.0 0.70
Albumin mg/dL 3.60.7 3.80.4 0.001Race 0.15
Caucasian 71% 78% Hematocrit % 34.25.0 36.15.6 0.006
Proteinuria g/day 2.02.4 1.52.0 0.12African American 12% 6%
Asian 16% 13% Hyperlipidemiab 28% 29% 0.83
Abnormal Ca-PO4Other 1% 3%
Insurance 0.92 metabolismc 18% 15% 0.55
Acidosisd 3% 7% 0.22Private 18% 16%
HMO 66% 68% Medications
ACE inhibitor 39% 52% 0.05Medicare 11% 10%
Medicaid 2% 3% Erythropoietin 4% 2% 0.39
Oral iron 8% 9% 0.66None 3% 3%
Cause of chronic kidney disease 0.001 Vitamin D 2% 3% 0.49
Lipid lowering agents 20% 16% 0.37Diabetes 33% 19%
Hypertension 28% 17% Abbreviations are: GFR, glomerular filtration rate; ACE, angiotensin con-
GN/IN/PKD 14% 39% verting enzyme; Ca, calcium; PO4, phosphorus.
Other 26% 25% a Probability value for comparison between hospitalized and non-hospitalized
Comorbid conditions patients
b Total serum cholesterol 200 mg/dL and/or use of anti-lipemicsCardiac diseases 54% 28% 0.001
c Parathyroid hormone level 100 pg/dL and/or serum phosphorus level 4.5Hypertension 88% 86% 0.66
mg/dL or use of calcitriol and/or phosphate bindersDiabetes 44% 27% 0.006
d Serum bicarbonate level 20 mmol/LCerebrovascular disease 18% 5% 0.001
Peripheral vascular disease 20% 7% 0.002
Abbreviations are: HMO, health maintenance organization; GN, glomerulo-
nephritis; PKD, polycystic kidney disease; IN, interstitial nephritis. Percentages
may not add up to 100 due to rounding. variate analyses using the GEE method incorporating
a Probability value for comparison between hospitalized and non-hospitalized
changes in patient characteristics over time revealed apatients
higher risk of hospitalization with increasing age (RR
1.01, 95% CI 1.00, 1.03), and among patients with cardiac
disease (RR 2.43, 95% CI 1.66, 3.58), cerebrovascular
24.5% of hospitalizations. Progression of CKD/acute disease (RR 1.89, 95% CI 1.12, 3.19) and peripheral
kidney failure was the most common secondary cause vascular disease (RR 1.66, 95% CI 1.02, 2.68). There
of hospitalization. was a lower risk of hospitalization among patients with
Time to first hospitalization. Univariate analyses using higher serum albumin (RR 0.48, 95% CI 0.35, 0.65),
Cox proportional hazards methodology revealed a higher hematocrit (RR 0.89, 95% CI 0.86, 0.93) and
higher risk of hospitalization associated with increasing among patients on ACE inhibitors (RR 0.64, 95% CI
age (RR 1.02, 95% CI 1.01, 1.03), and among patients 0.47, 0.88). Multivariate analyses revealed a higher risk
with cardiac disease (RR 1.69, 95% CI 1.15, 2.47), diabe- of hospitalization with increasing age (RR 1.02, 95% CI
tes (RR 1.67, 95% CI 1.12, 2.47), peripheral vascular 1.00, 1.03), and among patients with cardiac disease (RR
disease (RR 1.84, 95% CI 1.14, 2.97), and cerebrovascu- 1.91, 95% CI 1.19, 3.07). There was a lower risk of hospi-
lar disease (RR 1.76, 95% CI 1.07, 2.89). There was a talization among patients with higher serum albumin
lower risk of hospitalization among patients with GN/ (RR 0.58, 95% CI 0.35, 0.95) and higher hematocrit (RR
IN/PKD compared to hypertension as cause of CKD 0.92, 95% CI 0.87, 0.97).
(RR 0.43, 95% CI 0.24, 0.78), among patients on ACE- Risk of subsequent hospital days. Results of the multi-
inhibitors at baseline (RR 0.62, 95% CI 0.42, 0.91), and ple event model regression analyses are presented in
patients with higher baseline serum albumin (RR 0.53, Table 4. Univariate analyses using the GEE method
95% CI 0.38, 0.73). A multivariate analysis with age, revealed a higher risk of subsequent hospital days with
gender, race and diabetes forced into the model revealed increasing age (RR 1.01, 95% CI 1.00, 1.03), and among
a higher risk of hospitalization associated with increasing patients with cardiac disease (RR 3.18, 95% CI 1.78,
age (RR 1.02, 95% CI 1.00, 1.04), and a lower risk of 5.65), cerebrovascular disease (RR 2.32, 95% CI 1.17,
hospitalization among patients on angiotensin-convert- 4.60), peripheral vascular disease (RR 2.52, 95% CI 1.32,
ing enzyme (ACE) inhibitors at baseline (RR 0.63, 95% 4.80), and among patients with abnormal calcium-phos-
CI 0.41, 0.96) and with higher baseline serum albumin phorus metabolism (RR 1.50, 95% CI 1.10, 2.04) and on
(RR 0.49, 95% CI 0.33, 0.72). vitamin D (RR 1.26, 95% CI 1.00, 1.59). There was a
Risk of hospitalization. Results of the multiple event lower risk of subsequent hospital days with patients with
higher serum albumin (RR 0.35, 95% CI 0.23, 0.52),model regression analyses are presented in Table 3. Uni-
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Fig. 1. Primary () and secondary () causes
of hospitalization among patients with chronic
kidney disease. Abbreviations are: GU, genito-
urinary; GI, gastrointestinal; Psych, psychiatry;
CNS, central nervous system; CVA, cerebro-
vascular accident; CRF, chronic renal failure;
ARF, acute renal failure; PVD, peripheral vas-
cular disease; CHF, congestive heart failure;
HTN, hypertension.
Table 4. Relative risk of hospital days among patientsTable 3. Relative risk of hospitalization among patients
with chronic kidney disease with chronic kidney disease
Generalized estimating equationGeneralized estimating equation
Univariate MultivariateUnivariate Multivariate
Variables RR (95% CI) RR (95% CI) Variables RR (95% CI) RR (95% CI)
Age per year increase 1.01 (1.00, 1.03)a 1.02 (0.99, 1.05)Age per year increase 1.01 (1.00, 1.03)a 1.02 (1.00, 1.03)a
Male vs. female 0.75 (0.51, 1.12) 1.01 (0.62, 1.63) Male vs. female 0.71 (0.40, 1.26) 1.68 (0.83, 3.40)
White vs. non-white 0.77 (0.42, 1.44) 1.01 (0.50, 2.03)White vs. non-white 0.69 (0.44, 1.07) 0.82 (0.47, 1.44)
Comorbid conditions Co-morbid conditions
Diabetes 1.24 (0.68, 2.25) 1.10 (0.48, 2.48)Diabetes 1.50 (0.99, 2.29) 1.15 (0.72, 1.83)
Cardiac disease 2.43 (1.66, 3.58)a 1.91 (1.19, 3.07)a Cardiac disease 3.18 (1.78, 5.65)a
Cerebrovascular disease 2.32 (1.17, 4.60)aCerebrovascular disease 1.89 (1.12, 3.19)a
Peripheral vascular disease 1.66 (1.02, 2.68)a Peripheral vascular disease 2.52 (1.32, 4.80)a
Albumin per g/dL increase 0.35 (0.23, 0.52)a 0.34 (0.21, 0.55)aAlbumin per g/dL increase 0.48 (0.35, 0.65)a 0.58 (0.35, 0.95)a
Hematocrit per % increase 0.89 (0.86, 0.93)a 0.92 (0.87, 0.97)a Hematocrit per % increase 0.90 (0.83, 0.98)a 0.87 (0.81, 0.93)a
Abnormal Ca-PO4 metabolism 1.50 (1.10, 2.04)aACE inhibitor use vs. non-use 0.64 (0.47, 0.88)a
Vitamin D use vs. non-use 1.26 (1.00, 1.59)aa Significant associations
ACE-inhibitor use vs. non-use 0.52 (0.30, 0.92)a 0.63 (0.47, 0.84)a
a Significant associations
higher hematocrit (RR 0.90, 95% CI 0.83, 0.98), and
among patients on ACE inhibitors (RR 0.52, 95% CI vitamin D (RR 1.34, 95% CI 1.04, 1.74). There was a
0.30, 0.92). Multivariate analyses revealed a lower risk lower risk of outpatient nephrology visits among patients
of subsequent hospital days among patients with higher with higher hematocrit (RR 0.98, 95% CI 0.96, 0.99).
serum albumin (RR 0.34, 95% CI 0.21, 0.55), higher Multivariate analyses revealed a higher risk of outpatient
hematocrit (RR 0.87, 95% CI 0.81, 0.93) and among nephrology visits among patients on erythropoietin (RR
patients on ACE inhibitors (RR 0.63, 95% CI 0.47, 0.84). 1.47, 95% CI 1.11, 1.82), while none of the other factors
remained significant.
Outpatient nephrology visits
There were 4.0 outpatient nephrology visits per pa-
DISCUSSIONtient-year at risk. Results of the multiple event model
regression analyses are presented in Table 5. Univariate The current study reveals significant resource utiliza-
tion among patients with CKD. During a median follow-analyses using the GEE method revealed a higher risk
of outpatient nephrology visits among patients with ab- up of 11.4 months, 47% of patients had at least one
hospitalization, and there were on average 0.96 hospital-normal Ca-PO4 metabolism (RR 1.40, 95% CI 1.21, 1.61),
and among patients on erythropoietin (RR 1.54, 95% izations, 6.6 hospital days and 4.0 outpatient nephrology
visits per patient-year at risk. Cardiac disease/hyperten-CI 1.23, 1.92), iron (RR 1.38, 95% CI 1.08, 1.75), and
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Table 5. Relative risk of outpatient nephrology visits cause of hospitalization in our cohort. Furthermore, the
among patients with chronic kidney disease
prevalence of certain comorbid conditions in our CKD
Generalized estimating equation cohort was comparable to the prevalence in the U.S.
Univariate Multivariate dialysis population: cardiovascular disease (40 vs. 58.8%),
Variables RR (95% CI) RR (95% CI) cerebrovascular disease (12 vs. 8%), and peripheral vas-
Age per year increase 1.00 (1.00, 1.00) 1.00 (0.99, 1.00) cular disease (14 vs. 14%) [3]. The higher hospital utiliza-
Male vs. female 0.94 (0.78, 1.13) 0.97 (0.80, 1.16) tion among patients with CKD compared to the general
White vs. non-white 0.89 (0.72, 1.10) 0.89 (0.72, 1.11)
population and the similarity in the comorbid conditionsDiabetes 1.10 (0.90, 1.35) 0.99 (0.82, 1.20)
Creatinine per mg/dL and the causes of hospitalization between patients with
increase 0.99 (0.98, 1.00) CKD and ESRD patients, confirm the hypothesis that
GFR per mL/min/1.73 m2
the complications and comorbidity observed in ESRDdecrease 1.06 (0.98, 1.14)
Hematocrit per % increase 0.98 (0.96, 0.99)a manifest themselves well before the onset of ESRD.
Abnormal Ca-PO4 metabolism 1.40 (1.21, 1.61)a The results of this study in part support earlier findings
Erythropoietin use vs. non-use 1.54 (1.23, 1.92)a 1.47 (1.11, 1.82)a
regarding risk factors for hospital utilization among pa-Oral iron use vs. non-use 1.38 (1.08, 1.75)a
Vitamin D use vs. non-use 1.34 (1.04, 1.74)a tients with kidney failure. Previous studies have demon-
a Significant associations strated an association between age, gender, race, cardiac
disease, peripheral vascular disease, serum albumin and
hematocrit levels, and resource utilization among dialysis
[8, 13, 14] and pre-dialysis [15] patients. Older age has
sion was the most common primary diagnosis of hospital- been identified as an independent predictor of hospital-
izations, and progression of CKD/acute kidney failure ization in the ESRD population [13] and among patients
was the most common secondary cause of hospitaliza- identified as likely to progress to ESRD [15]. In addition,
tion. Multivariate analyses incorporating changes in co- older age is associated with increased morbidity and mor-
variates over time (generalized estimating equation) re- tality among ESRD patients [16–19]. The current analy-
vealed that older age and presence of cardiac disease ses incorporating changes in age over time also identified
were associated with a higher risk of hospitalization, an independent association between age and a higher
while higher serum albumin and higher hematocrit were risk of hospitalization.
associated with a lower risk of hospitalization. In addi- Comorbid conditions such as cardiovascular disease,
tion, higher albumin, higher hematocrit and ACE inhibi- ischemic heart disease and peripheral vascular disease
tor use were associated with lower risk of subsequent have been shown to be associated with increased hospi-
hospital days. Only erythropoietin use was associated talizations among ESRD [8, 14] and pre-dialysis [15]
with a higher risk of outpatient nephrology visits. patients. In the current study, cardiovascular comorbid-
The results confirm that hospital utilization among ity was strongly associated with an increased risk of hos-
patients with CKD is high. We have previously shown pitalization; however, the relationship was attenuated in
that the dialysis population at our institution had 2.2 hos- the multivariate analyses. This may reflect a stronger
pitalizations and 14.8 hospital days per patient-year at influence of other factors such as use of ACE inhibitors
risk [8], which was similar to that among U.S. hemodialy- and level of albumin and hematocrit (see paragraphs
sis patients between 1996 and 1998, who had 1.9 hospital- to follow), or an interplay between these factors and
izations and 14 hospital days per patient-year at risk [5]. cardiovascular disease. Alternatively, these factors may
In the general population, there were 0.31 hospitaliza- serve as markers for other unmeasured comorbid condi-
tions and 1.9 hospital days per person in 1998 [12]. Hospi- tions that affect risk of hospital utilization.
tal utilization among CKD patients was thus three times The benefit of ACE inhibitors in retarding the progres-
higher than among patients in the general population sion of kidney disease is fairly well established [20–22].
above the age of 15 years in a similar era and is in all Although this study was not designed to evaluate this
likelihood even higher than we described, as hospitaliza- outcome, the analyses did reveal a lower risk of hospital
tions outside of NEMC were not reliably captured. The utilization among patients recorded as using an ACE
causes of hospitalization among CKD patients in our inhibitor in both the traditional Cox proportional haz-
study were similar to those in the U.S. dialysis popula- ards model and the generalized estimating equation
tion, with the exception of vascular access hospitaliza- model assessing risk of subsequent hospital days. Given
tions, which are a frequent cause of hospitalization the high prevalence of ischemic and other cardiac dis-
among dialysis patients, and were rare in the current eases in this patient population, it may be postulated
CKD cohort [5, 8]. Cardiac complications were the lead- that ACE inhibitors reduce the risk of hospital utilization
ing cause of hospitalization among CKD patients, ac- by modification of cardiovascular risk factors, although
counting for 24.5% of all admissions, and this diagnostic the interaction between ACE inhibitor use and cardio-
vascular diseases was not significant. This may in partcategory was also the second most common secondary
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be explained by imperfect capture of cardiovascular con- Levels of kidney function examined as either serum
creatinine level or estimated GFR were not significantlyditions. Alternatively, ACE inhibitor use may be a surro-
gate for other factors that were not recorded, or may associated with any of the measures of resource utiliza-
tion evaluated in the current study. This is in contrastsimply reflect better access to care and improved man-
agement of other conditions. That is, patients presenting to the study by Holland and Lam, which noted that pa-
tients with serum creatinine levels 3.4 mg/dL had aregularly for care are more likely to be prescribed recom-
mended therapies. 64% increased risk of hospitalization compared to pa-
tients with lower serum creatinine levels in univariateLower serum albumin levels have been shown to be
associated with increased hospital utilization [8, 14] and analysis. However, this relationship was not seen in mul-
tivariate analyses [15]. Serum creatinine may not be asmortality [16, 23] in the ESRD population. In the current
study, higher serum albumin was independently associ- strong a marker for other undefined conditions as has
been speculated. If this were indeed the case, risk strati-ated with a lower risk of hospital utilization, but was
not associated with frequency of outpatient nephrology fication primarily based on level of kidney function with-
out taking into consideration other comorbid conditionsvisits. Albumin is considered a marker of nutrition, and
hence, it could be inferred that well nourished patients may be misguided, and may potentially result in misallo-
cation of resources.are at lower risk of adverse outcomes. However, other
non-nutritional factors are also important determinants To our knowledge, most investigators evaluating the
association between risk factors and clinical or economicof albumin level. It is a negative acute phase reactant,
and acute or chronic medical conditions have an impact outcomes among patients with CKD or ESRD have gen-
erally assessed only the impact of baseline factors onon its synthesis [24]. Thus, the independent association
of serum albumin may be the reflection of underlying subsequent outcomes. The GEE methodology used in
this study incorporates potentially changing covariatesdisease severity. Consequently, although low serum albu-
min levels may serve to identify patients at greater risk in the analysis of repeated outcomes. This may provide
a more accurate assessment of the particular factor’s im-for hospitalization, whether closer surveillance and inter-
ventions targeted at improving serum albumin levels pact, or alternatively provide more accurate adjustment,
especially as some factors, such as albumin and hemato-would lead to less morbidity remains to be proven.
We found a significant association between hematocrit crit, may be expected to change with time and advancing
kidney disease.levels and the risk of hospitalization and hospital days.
Higher hematocrit levels have been shown to be associ- The results of this study must be interpreted with its
limitations in mind. It is a retrospective study with vari-ated with a lower risk of hospitalization among patients
with ESRD [6] and CKD [15], and with a lower mortality able ascertainment of data and follow-up. Specifically,
medications recorded in the chart may not reflect theamong patients with ESRD [25]. The impact of anemia
may possibly be attributed to its relationship with cardio- actual use of the medication, thus the impact of medica-
tions on outcomes must be considered with caution. Hos-vascular complications, given the high morbidity associ-
ated with cardiovascular conditions in this population. pitalizations outside of NEMC were not reliably cap-
tured, and only nephrology visits were analyzed, as weAlternatively, other comorbid conditions leading to ane-
mia, for which anemia serves as a marker, also may were primarily interested in nephrology-specific care.
Thus utilization is actually higher than we described. Incontribute to hospitalizations.
There is paucity of information on the factors asso- addition, the study is based in a tertiary care center, the
patient population was predominantly Caucasian, andciated with outpatient utilization among patients with
chronic kidney disease. In a recent study of dialysis pa- there was a relatively high prevalence of Asians and low
prevalence of African Americans due to our center’stients at our center, diabetes, younger age, Caucasian
race and late referral to nephrology (that is, first nephrol- location in the Chinatown district of Boston. The relative
under-representation of African American is related toogy visit less than 4 months prior to the initiation of
dialysis) were shown to be independently associated with the overall demographic mix representative of the pa-
tients at our institution, and is not a selection bias of thehigher number of outpatient nephrology visits [8]. In the
current study, only erythropoietin use was significantly study. Finally, a majority of the patients had some form
of managed care insurance. These limitations may leadassociated with outpatient utilization. This may simply
reflect that erythropoietin administration occurs most to under- or overestimation of the hospitalization risk,
or to a lack of generalizability.often at the physician’s office and thus involves frequent
visits. Alternatively, patients presenting more frequently Despite these limitations, this study provides an over-
view of the resource utilization among patients withfor care are more likely to be diagnosed with a condition
requiring treatment and thus to have the initiation of CKD in the United States and identifies potential factors
associated with increased utilization. Targeting these fac-specific therapies. Thus, similarly as with ACE inhibitor
use, erythropoietin use may reflect better access to care. tors with timely interventions could translate into re-
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nation Survey. Am J Kidney Dis 32:992–999, 1998 (erratum: Amduced morbidity and mortality, and potentially reduced
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hospital utilization and cost. Future prospective studies 10. Greenfield S, Nelson E: Recent developments and future issues
in the use of health status assessment measures in clinical setting.are required to determine potential causal relationships
Med Care 30:23–41, 1992between improvements in these modifiable factors and
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